Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Renal Cell 71Prostatic Neoplasms 22Kidney Neoplasms 14Carcinoma, Transitional Cell 9Urinary Bladder Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Hepatocellular 6Urethral Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Urologic Neoplasms 2Urogenital Neoplasms 2Ureteral Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Recurrence 2Penile Neoplasms 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Melanoma 2

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Busulfan 4Filgrastim 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2cabozantinib 2Vemurafenib 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Sirolimus 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × cabozantinib × Genitourinary × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05135975 2025-08-12

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Nationwide Children's Hospital

Phase 2 Recruiting
86 enrolled
CNSGenitourinarySarcoma

Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡